{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:54:13Z","timestamp":1793051653315,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,5,15]],"date-time":"2018-05-15T00:00:00Z","timestamp":1526342400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.antiviral.2018.05.005","type":"journal-article","created":{"date-parts":[[2018,5,15]],"date-time":"2018-05-15T11:31:19Z","timestamp":1526383879000},"page":"76-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":194,"special_numbering":"C","title":["Innovation and trends in the development and approval of antiviral medicines: 1987\u20132017 and beyond"],"prefix":"10.1016","volume":"155","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4934-8556","authenticated-orcid":false,"given":"Shuvam","family":"Chaudhuri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian A.","family":"Symons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Deval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2018.05.005_bib1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12977-017-0360-7","article-title":"HIV drug resistance against strand transfer integrase inhibitors","volume":"14","author":"Anstett","year":"2017","journal-title":"Retrovirology"},{"key":"10.1016\/j.antiviral.2018.05.005_bib2","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3851\/IMP2629","article-title":"Comparing influenza and RSV viral and disease dynamics in experimentally infected adults predicts clinical effectiveness of RSV antivirals","volume":"18","author":"Bagga","year":"2013","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2018.05.005_bib3","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1021\/jm500335h","article-title":"Discovery of daclatasvir, a pan-genotypic hepatitis C virus NS5A replication complex inhibitor with potent clinical effect","volume":"57","author":"Belema","year":"2014","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.antiviral.2018.05.005_bib4","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00560-17","article-title":"Capsid assembly modulators have a dual mechanism of action in primary human hepatocytes infected with hepatitis B virus","volume":"61","author":"Berke","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.05.005_bib5","doi-asserted-by":"crossref","first-page":"e236","DOI":"10.1038\/mtna.2015.10","article-title":"Engineering cellular resistance to HIV-1 infection in vivo using a dual therapeutic lentiviral vector. Molecular therapy","volume":"4","author":"Burke","year":"2015","journal-title":"Nucleic Acids"},{"key":"10.1016\/j.antiviral.2018.05.005_bib6","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1128\/AAC.04623-14","article-title":"Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit","volume":"59","author":"Byrn","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.05.005_bib7","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMp1613362","article-title":"Broadly neutralizing antibodies for HIV-1 prevention or immunotherapy","volume":"375","author":"Caskey","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.05.005_bib8","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00737-17","article-title":"Preclinical characterization of PC786, an inhaled small-molecule respiratory syncytial virus L protein polymerase inhibitor","volume":"61","author":"Coates","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"10.1016\/j.antiviral.2018.05.005_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-003028","article-title":"Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US medicaid population with HIV","volume":"3","author":"Cohen","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.antiviral.2018.05.005_bib10","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1021\/jm030558s","volume":"47","author":"Das","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.05.005_bib11","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1128\/AAC.01802-15","article-title":"Generation and characterization of ALX-0171, a potent novel therapeutic nanobody for the treatment of respiratory syncytial virus infection","volume":"60","author":"Detalle","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.05.005_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004995","article-title":"Molecular basis for the selective inhibition of respiratory syncytial virus RNA polymerase by 2'-fluoro-4'-chloromethyl-cytidine triphosphate","volume":"11","author":"Deval","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2018.05.005_bib13","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1056\/NEJMoa1413275","article-title":"Activity of oral ALS-008176 in a respiratory syncytial virus challenge study","volume":"373","author":"DeVincenzo","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.05.005_bib14","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1401184","article-title":"Oral GS-5806 activity in a respiratory syncytial virus challenge study","volume":"371","author":"DeVincenzo","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.05.005_bib15","first-page":"171","article-title":"First newborn baby to receive experimental therapies survives Ebola virus disease","volume":"215","author":"Dornemann","year":"2017","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.05.005_bib16","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1517\/14728214.2016.1162155","article-title":"Emerging drugs for the treatment of hepatitis B","volume":"21","author":"Fung","year":"2016","journal-title":"Expert Opin. Emerg. drugs"},{"key":"10.1016\/j.antiviral.2018.05.005_bib17","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.coph.2016.07.014","article-title":"HCV NS5A replication complex inhibitors","volume":"30","author":"Gao","year":"2016","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.antiviral.2018.05.005_bib18","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01714-16","article-title":"Safety, tolerability, and pharmacokinetics of MEDI8897, the respiratory syncytial virus prefusion F-Targeting monoclonal antibody with an extended half-life, in healthy adults","volume":"61","author":"Griffin","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.05.005_bib19","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1604330","article-title":"A randomized, controlled trial of ZMapp for Ebola virus infection","volume":"375","author":"Group","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.05.005_bib20","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(16)30386-5","article-title":"Late Ebola virus relapse causing meningoencephalitis: a case report","volume":"388","author":"Jacobs","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2018.05.005_bib21","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/COH.0000000000000374","article-title":"Universal antiretroviral regimens: thinking beyond one-pill-once-a-day","volume":"12","author":"Jacobson","year":"2017","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.antiviral.2018.05.005_bib22","doi-asserted-by":"crossref","first-page":"40847","DOI":"10.1074\/jbc.M106743200","article-title":"Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase","volume":"276","author":"Johnson","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2018.05.005_bib23","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/nbt.1638","article-title":"Identification of influenza A nucleoprotein as an antiviral target","volume":"28","author":"Kao","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.antiviral.2018.05.005_bib24","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/978-1-59745-394-3_27","article-title":"Adaptation of the hepatitis C virus to cell culture","volume":"510","author":"Kaul","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.antiviral.2018.05.005_bib25","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1517\/14656566.5.12.2567","article-title":"Docosanol: a topical antiviral for herpes labialis","volume":"5","author":"Leung","year":"2004","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.antiviral.2018.05.005_bib26","first-page":"95","article-title":"HIV protease inhibitors: a review of molecular selectivity and toxicity","volume":"7","author":"Lv","year":"2015","journal-title":"Hiv\/Aids"},{"key":"10.1016\/j.antiviral.2018.05.005_bib27","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/COH.0000000000000169","article-title":"Long-acting antiviral agents for HIV treatment","volume":"10","author":"Margolis","year":"2015","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.antiviral.2018.05.005_bib28","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.coph.2016.07.015","article-title":"Hepatitis C virus NS3\/4a protease inhibitors","volume":"30","author":"McCauley","year":"2016","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.antiviral.2018.05.005_bib29","doi-asserted-by":"crossref","first-page":"6246","DOI":"10.1128\/AAC.00977-13","article-title":"Efficacy of tecovirimat (ST-246) in nonhuman primates infected with variola virus (Smallpox)","volume":"57","author":"Mucker","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.05.005_bib30","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/1087057114556253","article-title":"High-content image-based screening of a signal transduction pathway inhibitor small-molecule library against highly pathogenic RNA viruses","volume":"20","author":"Mudhasani","year":"2015","journal-title":"J. Biomol. Screen."},{"key":"10.1016\/j.antiviral.2018.05.005_bib31","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1128\/AAC.01184-07","article-title":"The mechanism of action of beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine involves a second metabolic pathway leading to beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine 5'-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase","volume":"52","author":"Murakami","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.05.005_bib32","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.coviro.2011.10.030","article-title":"Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action","volume":"1","author":"Paeshuyse","year":"2011","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.antiviral.2018.05.005_bib33","doi-asserted-by":"crossref","first-page":"23569","DOI":"10.1074\/jbc.M116.753384","article-title":"A new class of allosteric HIV-1 integrase inhibitors identified by crystallographic fragment screening of the catalytic core domain","volume":"291","author":"Patel","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2018.05.005_bib34","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.antiviral.2011.10.002","article-title":"Celgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-survival genes and protects against lethal challenge mouse model","volume":"92","author":"Rathore","year":"2011","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.05.005_bib35","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41467-017-00170-x","article-title":"Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor","volume":"8","author":"Roymans","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.antiviral.2018.05.005_bib36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41541-017-0019-3","article-title":"Antibody therapies for the prevention and treatment of viral infections","volume":"2","author":"Salazar","year":"2017","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.antiviral.2018.05.005_bib37","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nrd4035","article-title":"What matters most in commercial success: first-in-class or best-in-class? Nature reviews","volume":"12","author":"Schulze","year":"2013","journal-title":"Drug Discov."},{"key":"10.1016\/j.antiviral.2018.05.005_bib38","article-title":"Experimental treatment with favipiravir for Ebola virus disease (the JIKI trial): a historically controlled, single-arm proof-of-concept trial in Guinea","volume":"13","author":"Sissoko","year":"2016","journal-title":"PLoS Med."},{"key":"10.1016\/j.antiviral.2018.05.005_bib39","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.3390\/v6082960","article-title":"The emerging profile of cross-resistance among the nonnucleoside HIV-1 reverse transcriptase inhibitors","volume":"6","author":"Sluis-Cremer","year":"2014","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2018.05.005_bib40","doi-asserted-by":"crossref","first-page":"14138","DOI":"10.1073\/pnas.0906467106","article-title":"Essential role of platelet-activating factor receptor in the pathogenesis of Dengue virus infection","volume":"106","author":"Souza","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2018.05.005_bib41","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJMoa1300662","article-title":"Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV","volume":"370","author":"Tebas","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.05.005_bib42","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2018.05.005_bib43","doi-asserted-by":"crossref","first-page":"22791","DOI":"10.1038\/srep22791","article-title":"A generic screening platform for inhibitors of virus induced cell fusion using cellular electrical impedance","volume":"6","author":"Watterson","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2018.05.005_bib44","doi-asserted-by":"crossref","first-page":"e1694","DOI":"10.1038\/cddis.2015.42","article-title":"T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance","volume":"6","author":"Ye","year":"2015","journal-title":"Cell Death Dis."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218301803?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218301803?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:27:08Z","timestamp":1759062428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354218301803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":44,"alternative-id":["S0166354218301803"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.05.005","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innovation and trends in the development and approval of antiviral medicines: 1987\u20132017 and beyond","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}